The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive…
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s…
Obesity is recognized as a chronic disease and public health concern globally. The primary goals of obesity treatment are to improve patients’ health outcomes and quality of life. Physicians…
The landmark FDA approval of Biogen / Eisai’s aducanumab (Aduhelm) in 2021 has had a minimal effect on treatment dynamics in AD owing to the lack of reimbursement and the controversy surrounding…
Obesity is a significant and growing public health concern in the G7 countries. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing…
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…
In 2022, sales of insulins at the ex-manufacturer price level exceeded $16 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast…
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. Key treatment goals…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis market has been a lucrative space for drug…
NHL and CLL encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes. Treatment approaches vary by subtype, with rituximab in…
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive…